Regarding CTLA4, it is well known that it is the second target of checkpoint inhibition therapeutic approaches in RCC, and CTLA4 expression was significantly correlated with metastatic diseases and associated with a reduced survival in ccRCC [36]. Here, CTLA4 is linked to metastatic neoplasm.